Literature DB >> 8945584

Resistance to mycoplasmal lung disease in mice is a complex genetic trait.

S C Cartner1, J W Simecka, D E Briles, G H Cassell, J R Lindsey.   

Abstract

Mouse strains differ markedly in resistance to Mycoplasma pulmonis infection, and investigation of these differences holds much promise for understanding the mechanisms of antimycoplasmal host defenses. To determine the potential genetic diversity of resistance to disease in murine respiratory mycoplasmosis (MRM) and to select disease-resistant and nonresistant mouse strains for further genetic analysis, we screened 17 inbred mouse strains of various Bcg and H-2 genotypes for resistance to M. pulmonis. Mice were inoculated intranasally with 10(4) CFU of M. pulmonis UAB CT and evaluated at 21 days postinfection for severities of the four histologic lung lesions characteristic of MRM: alveolar exudate, airway exudate, airway epithelial hyperplasia, and lymphoid infiltrate. On the basis of these assessments of MRM severity, one group of mouse strains was found to be extremely resistant to disease (C57BR/cdJ, C57BL/6NCr, C57BL/10ScNCr, and C57BL/6J). The remaining strains of mice (C57L/J, SJL/NCr, BALB/cAnNCr, A/JCr, C3H/HeJ, SWR/J, AKR/NCr, CBA/NCr, C58/J, DBA/2NCr, C3H/HeNCr, C3HeB/FeJ, and C3H/HeJCr) developed disease of widely varying severities. Furthermore, strains in the group with more disease varied in pattern of lesion severity. While the severities of all four lesions were correlated in most mouse strains, this was not always true. DBA/2NCr mice had one of the highest scores for alveolar exudate, only a moderate score for airway exudate, and significantly lower scores for both airway epithelial hyperplasia and lymphoid infiltrate than all other strains susceptible to lung disease. DBA/2NCr mice had one of the highest mortality rates. We concluded that resistance to MRM is a complex trait. The observed differences in lung disease severity could not be explained by known differences at the Bcg or H-2 locus in the strains of mice we studied.

Entities:  

Mesh:

Year:  1996        PMID: 8945584      PMCID: PMC174526          DOI: 10.1128/iai.64.12.5326-5331.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  The significance of infection as a cause of death in veterans.

Authors:  D J Flournoy; J B Jones
Journal:  Mil Med       Date:  1987-11       Impact factor: 1.437

2.  Protection of mice against Mycoplasma pulmonis infection using purified mouse immunoglobulins: comparison between protective effect and biological properties of immunoglobulin classes.

Authors:  G Taylor; C J Howard
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

3.  Strain differences in susceptibility to murine respiratory mycoplasmosis in C57BL/6 and C3H/HeN mice.

Authors:  J K Davis; R F Parker; H White; D Dziedzic; G Taylor; M K Davidson; N R Cox; G H Cassell
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

4.  Derrick Edward Award Lecture. The pathogenic potential of mycoplasmas: Mycoplasma pulmonis as a model.

Authors:  G H Cassell
Journal:  Rev Infect Dis       Date:  1982 May-Jun

5.  Pulmonary clearance of Mycoplasma pulmonis in C57BL/6N and C3H/HeN mice.

Authors:  R F Parker; J K Davis; D K Blalock; R B Thorp; J W Simecka; G H Cassell
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

6.  Evaluation by scoring and computerized morphometry of lesions of early Mycoplasma pulmonis infection and ammonia exposure in F344/N rats.

Authors:  D M Pinson; T R Schoeb; J R Lindsey; J K Davis
Journal:  Vet Pathol       Date:  1986-09       Impact factor: 2.221

7.  Interactions between murine alveolar macrophages and Mycoplasma pulmonis in vitro.

Authors:  J K Davis; K M Delozier; D K Asa; F C Minion; G H Cassell
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

8.  Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia.

Authors:  C M Roifman; C P Rao; H M Lederman; S Lavi; P Quinn; E W Gelfand
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

9.  Differences in virulence for mice among strains of Mycoplasma pulmonis.

Authors:  M K Davidson; J R Lindsey; R F Parker; J G Tully; G H Cassell
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

10.  Critical dependence on antibody for defence against mycoplasmas.

Authors:  A D Webster; P M Furr; N C Hughes-Jones; B D Gorick; D Taylor-Robinson
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

View more
  19 in total

1.  Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite.

Authors:  J Hickman-Davis; J Gibbs-Erwin; J R Lindsey; S Matalon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Spiralin, a mycoplasmal membrane lipoprotein, induces T-cell-independent B-cell blastogenesis and secretion of proinflammatory cytokines.

Authors:  C Brenner; H Wróblewski; M Le Henaff; L Montagnier; A Blanchard
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 3.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  Reactive species mediate inhibition of alveolar type II sodium transport during mycoplasma infection.

Authors:  Judy M Hickman-Davis; Carmel McNicholas-Bevensee; Ian C Davis; He-Ping Ma; Glenda C Davis; Charles A Bosworth; Sadis Matalon
Journal:  Am J Respir Crit Care Med       Date:  2005-10-27       Impact factor: 21.405

5.  Cyclophosphamide decreases nitrotyrosine formation and inhibits nitric oxide production by alveolar macrophages in mycoplasmosis.

Authors:  J M Hickman-Davis; J R Lindsey; S Matalon
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  THE MULTIFACETED ROLE OF T CELL-MEDIATED IMMUNITY IN PATHOGENESIS AND RESISTANCE TO MYCOPLASMA RESPIRATORY DISEASE.

Authors:  Nicole A Dobbs; Adam N Odeh; Xiangle Sun; Jerry W Simecka
Journal:  Curr Trends Immunol       Date:  2009

7.  Interleukin-17A Exacerbates Disease Severity in BALB/c Mice Susceptible to Lung Infection with Mycoplasma pulmonis.

Authors:  Maximillion T Mize; Xiangle L Sun; Jerry W Simecka
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

8.  Cytokine and chemokine transcription profile during Mycoplasma pulmonis infection in susceptible and resistant strains of mice: macrophage inflammatory protein 1beta (CCL4) and monocyte chemoattractant protein 2 (CCL8) and accumulation of CCR5+ Th cells.

Authors:  Xiangle Sun; Harlan P Jones; Lisa M Hodge; Jerry W Simecka
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

9.  A novel IL-17-dependent mechanism of cross protection: respiratory infection with mycoplasma protects against a secondary listeria infection.

Authors:  Amy N Sieve; Karen D Meeks; Sheetal Bodhankar; Suheung Lee; Jay K Kolls; Jerry W Simecka; Rance E Berg
Journal:  Eur J Immunol       Date:  2009-02       Impact factor: 5.532

10.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.